Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 107.8%

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 332,658 shares, a growth of 107.8% from the June 15th total of 160,118 shares. Based on an average daily trading volume, of 5,613,473 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the company’s shares are short sold.

Institutional Trading of Entera Bio

Hedge funds have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC raised its stake in Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after buying an additional 29,629 shares during the period. Jane Street Group LLC grew its stake in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after acquiring an additional 43,536 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after acquiring an additional 19,601 shares in the last quarter. Superstring Capital Management LP bought a new stake in shares of Entera Bio in the fourth quarter worth about $33,000. Finally, HighTower Advisors LLC raised its position in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Stock Up 9.9%

Entera Bio stock traded up $0.16 during midday trading on Wednesday, hitting $1.78. 227,651 shares of the stock were exchanged, compared to its average volume of 593,309. The stock has a market capitalization of $87.74 million, a PE ratio of -6.59 and a beta of 1.43. The company has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $1.38. Entera Bio has a 52 week low of $0.91 and a 52 week high of $3.22.

Entera Bio (NASDAQ:ENTX) last issued its earnings results on Friday, May 8th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. As a group, equities research analysts anticipate that Entera Bio will post -0.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ENTX. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

About Entera Bio

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.